Citations (79)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Monika Kozieł, Stefan Simovic, Nikola Pavlovic, Aleksandar Kocijancic, Vilma Paparisto, Ljilja Music, Elina Trendafilova, Anca Rodica Dan, Zumreta Kusljugic, Gheorghe-Andrei Dan, Gregory Y. H. Lip & Tatjana S. Potpara. (2021) Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation: insights from the BALKAN-AF survey. Annals of Medicine 53:1, pages 17-25.
Read now
Read now
Julia Seeger & Jochen Wöhrle. (2020) Apixaban: An Update of the Evidence for Its Place in the Prevention of Stroke in Patients with Atrial Fibrillation. Core Evidence 15, pages 1-6.
Read now
Read now
Mauro Monelli, Mauro Molteni, Giuseppina Cassetti, Laura Bagnara, Valeria De Grazia, Lorenza Zingale, Franca Zilli, Maurizio Bussotti, Paolo Totaro, Beatrice De Maria & Laura Adelaide Dalla Vecchia. (2019) Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study – data from the REGIstry of patients on Non-vitamin K oral Anticoagulants (REGINA). Vascular Health and Risk Management 15, pages 19-25.
Read now
Read now
Ritam Chowdhury, Jessica Franchino-Elder, Li Wang, Huseyin Yuce, Cheng Wang & Briain O. Hartaigh. (2019) Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants. Journal of Medical Economics 22:12, pages 1338-1350.
Read now
Read now
Cesar Caro Martinez, Juan José Cerezo Manchado, Pedro José Flores Blanco, Ginés Elvira Ruíz, Helena Albendín Iglesias, Alejandro Lova Navarro, Francisco Arregui Montoya, Arcadio García Alberola, Domingo Andrés Pascual Figal, Jose Luis Bailén Lorenzo, Begoña Navarro-Almenzar, Faustino García-Candel & Sergio Manzano Fernández. (2019) Effectiveness and safety of rivaroxaban in nonvalvular atrial fibrillation: data from a contemporary Spanish registry. Current Medical Research and Opinion 35:8, pages 1463-1471.
Read now
Read now
Ameenathul M. Fawzy, Wang-Yang Yang & Gregory YH. Lip. (2019) Safety of direct oral anticoagulants in real–world clinical practice: translating the trials to everyday clinical management. Expert Opinion on Drug Safety 18:3, pages 187-209.
Read now
Read now
Jean-Baptiste Briere, Kevin Bowrin, Craig Coleman, Laurent Fauchier, Pierre Levy, Kerstin Folkerts, Mondher Toumi, Vanessa Taieb, Aurélie Millier & Olivia Wu. (2019) Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review. Expert Review of Pharmacoeconomics & Outcomes Research 19:1, pages 27-36.
Read now
Read now
Pierre Levy, David M. Smadja, Julie Dorey, Mondher Toumi, Anna-Katharina Meinecke, Kevin Bowrin & Jean-Baptiste Briere. (2019) Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective. Journal of Market Access & Health Policy 7:1.
Read now
Read now
Ylenia Ingrasciotta, Salvatore Crisafulli, Valeria Pizzimenti, Ilaria Marcianò, Anna Mancuso, Giuseppe Andò, Salvatore Corrao, Piera Capranzano & Gianluca Trifirò. (2018) Pharmacokinetics of new oral anticoagulants: implications for use in routine care. Expert Opinion on Drug Metabolism & Toxicology 14:10, pages 1057-1069.
Read now
Read now
Shun Kohsaka, Jun Katada, Kumiko Saito & Yasuo Terayama. (2018) Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data. Current Medical Research and Opinion 34:9, pages 1627-1634.
Read now
Read now
Yesenia Pimentel Quezada, Juan Luis Bonilla Palomas, Antonio Luis Gámez López, Mirian Moreno Conde, María Cristina López Ibáñez & Ángel Gallego de la Sacristana López-Serrano. (2018) Has the Clinical Profile of Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban Changed in the Last 5 Years of use?. Future Cardiology 14:sup3, pages 47-53.
Read now
Read now
Juan José Cerezo-Manchado, Begoña Navarro-Almenzar, Ginés Elvira-Ruiz, Faustino García-Candel, Pedro José Flores-Blanco, Cesar Caro-Martínez, Sergio Manzano-Fernández, Natalia García-Iniesta, Javier Sánchez-García, Valentín Cabañas-Perianes & José María Moraleda-Jiménez. (2018) Effectiveness and Safety of Rivaroxaban in a Cohort of 142 Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban for the Prevention of Stroke. Future Cardiology 14:sup3, pages 31-37.
Read now
Read now
Carlos Escobar Cervantes. (2018) Rivaroxaban: From ROCKET-AF Trial to Routine Practice in Spain. Future Cardiology 14:sup3, pages 1-2.
Read now
Read now
Gregory Y.H. Lip. (2016) How to REVISIT the increasing “real world” evidence for stroke prevention in non-valvular atrial fibrillation?. Current Medical Research and Opinion 32:12, pages 2055-2057.
Read now
Read now
Articles from other publishers (65)
Paul P. Dobesh & Toby C. Trujillo. (2023)
Comment on the 2023 updated
AGS
Beers Criteria for potentially inappropriate medication use in older adults
. Journal of the American Geriatrics Society 72:2, pages 631-633.
Crossref
Crossref
Nicholas Bovio, Genevieve M. Abd, Jennifer C. Ku, Leah C. Liu & Yong Li. 2024. Human Physiology - Annual Volume 2024 [Working Title]. Human Physiology - Annual Volume 2024 [Working Title].
Ki Hong Lee & Hyung Wook Park. (2023) Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. The Korean Journal of Internal Medicine 38:5, pages 583-594.
Crossref
Crossref
Hans Wille. 2023. Arzneiverordnungs-Report 2023. Arzneiverordnungs-Report 2023
255
287
.
Riccardo VIO, Andrea S. GIORDANI, Ahmed ALTURKI, Viktor ČULIć, Raffaele VITALE, Paolo CHINA, Sakis THEMISTOCLAKIS, Emilio VANOLI & Riccardo PROIETTI. (2022) Prevalence of asymptomatic atrial fibrillation among multimorbid elderly patients: diagnostic implications. Minerva Cardiology and Angiology 70:5.
Crossref
Crossref
Benjamin J. R. Buckley, Deirdre A. Lane, Peter Calvert, Juqian Zhang, David Gent, C. Daniel Mullins, Paul Dorian, Shun Kohsaka, Stefan H. Hohnloser & Gregory Y. H. Lip. (2022) Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine 11:13, pages 3788.
Crossref
Crossref
Fang Ma, Li Yuan, Xinli Wen, Yangyang Wang, Qiaofei Li & Chu Chen. (2022) Efficacy and Safety of Direct Oral Anticoagulants in Stable Coronary Artery Disease and Atrial Fibrillation: A Systematic Review and Network Meta-Analysis. Clinical and Applied Thrombosis/Hemostasis 28, pages 107602962211310.
Crossref
Crossref
Hans Wille. 2022. Arzneiverordnungs-Report 2022. Arzneiverordnungs-Report 2022
233
263
.
Carlos Escobar, Vivencio Barrios, Gregory Y. H. Lip, Alpesh N. Amin, Ariadna Auladell-Rispau, Marilina Santero, Josefina Salazar & Carolina Requeijo. (2021) Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis. Clinical Drug Investigation 41:11, pages 941-953.
Crossref
Crossref
Mirjam Hempenius, Rolf H. H. Groenwold, Patrick C. Souverein, Anthonius de Boer, Olaf H. Klungel & Helga Gardarsdottir. (2021) Impact of anticoagulant exposure misclassification on the bleeding risk of direct oral anticoagulants. British Journal of Clinical Pharmacology 87:9, pages 3508-3517.
Crossref
Crossref
Mario Bo, Alberto Corsini, Enrico Brunetti, Gianluca Isaia, Maddalena Gibello, Nicola Ferri, Daniela Poli, Niccolò Marchionni & Gaetano Maria De Ferrari. (2021) Off-label use of reduced dose direct oral factor Xa inhibitors in subjects with atrial fibrillation: a review of clinical evidence. European Heart Journal - Cardiovascular Pharmacotherapy 7:4, pages 334-345.
Crossref
Crossref
Monika Kozieł, Christine Teutsch, Jonathan L. Halperin, Kenneth J. Rothman, Hans-Christoph Diener, Chang-Sheng Ma, Sabrina Marler, Shihai Lu, Venkatesh K. Gurusamy, Menno V. Huisman & Gregory Y. H. Lip. (2021) Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF. PLOS ONE 16:4, pages e0249524.
Crossref
Crossref
Valentina Lorenzoni, Salvatore Pirri & Giuseppe Turchetti. (2021) Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available “Real-World” Evidence: The Italian National Health System Perspective. Clinical Drug Investigation 41:3, pages 255-267.
Crossref
Crossref
Peter L. Gross & Noel C. Chan. (2021) Thromboembolism in Older Adults. Frontiers in Medicine 7.
Crossref
Crossref
Sergio Cinza-Sanjurjo, Daniel Rey-Aldana, Manuel Portela-Romero & José R. González-Juanatey. (2021) Inercia terapéutica en anticoagulación oral en los pacientes con fibrilación auricular no valvular en atención primaria. Estudio ANFAGAL+. REC: CardioClinics 56:1, pages 22-29.
Crossref
Crossref
Hans Wille. 2021. Arzneiverordnungs-Report 2021. Arzneiverordnungs-Report 2021
299
326
.
Jacques Bouget, Frédéric Balusson, Maxime Maignan, Laure Pavageau, Pierre‐Marie Roy, Karine Lacut, Lucie‐Marie Scailteux, Emmanuel Nowak & Emmanuel Oger. (2020) Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3‐year period population‐based prospective cohort study. British Journal of Clinical Pharmacology 86:12, pages 2519-2529.
Crossref
Crossref
Magdalena Domek, Jakub Gumprecht, Wern Yew Ding, Gregory Y H Lip & Deirdre A Lane. (2020) Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials. European Heart Journal Supplements 22:Supplement_I, pages I1-I12.
Crossref
Crossref
Peter Magnusson, Joseph V. Pergolizzi Jr, Randall K. Wolf, Morten Lamberts & Jo Ann LeQuang. 2020. Epidemiology and Treatment of Atrial Fibrillation. Epidemiology and Treatment of Atrial Fibrillation.
Cosmo Godino, Francesco Melillo, Barbara Bellini, Mattia Mazzucca, Carlo Andrea Pivato, Francesca Rubino, Filippo Figini, Patrizio Mazzone, Paolo Della Bella, Alberto Margonato, Antonio Colombo & Matteo Montorfano. (2020) Percutaneous left atrial appendage closure versus non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation and high bleeding risk. EuroIntervention 15:17, pages 1548-1554.
Crossref
Crossref
Zhi-Chun Gu, An-Hua Wei, Chi Zhang, Xin-Hua Wang, Le Zhang, Long Shen, Zheng Li, Mang-Mang Pan, Xiao-Yan Liu, Jun Pu & Hou-Wen Lin. (2020) Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 18:4, pages 792-799.e61.
Crossref
Crossref
Joana Santos, Natália António, Marília Rocha & Ana Fortuna. (2020) Impact of direct oral anticoagulant off‐label doses on clinical outcomes of atrial fibrillation patients: A systematic review. British Journal of Clinical Pharmacology 86:3, pages 533-547.
Crossref
Crossref
Mark AlbertsYen-Wen ChenJennifer H. LinEmily KoganKathryn TwymanDejan Milentijevic. (2020) Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin. Stroke 51:2, pages 549-555.
Crossref
Crossref
Lutz Hein & Hans Wille. 2020. Arzneiverordnungs-Report 2020. Arzneiverordnungs-Report 2020
395
420
.
Raffaele De Caterina, Peter Kelly, Pedro Monteiro, Jean Claude Deharo, Carlo de Asmundis, Esteban López-de-Sá, Thomas W. Weiss, Johannes Waltenberger, Jan Steffel, Joris R. de Groot, Pierre Levy, Ameet Bakhai, Wolfgang Zierhut, Petra Laeis, Michael Kerschnitzki, Paul-Egbert Reimitz & Paulus Kirchhof. (2019) Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). BMC Cardiovascular Disorders 19:1.
Crossref
Crossref
Masaya Shinohara, Ryou Wada, Shintaro Yao, Kensuke Yano, Katsuya Akitsu, Hideki Koike, Toshio Kinoshita, Hitomi Yuzawa, Takeya Suzuki, Tadashi Fujino & Takanori Ikeda. (2019) Evaluation of oral anticoagulants in atrial fibrillation patients over 80 years of age with nonsevere frailty. Journal of Arrhythmia 35:6, pages 795-803.
Crossref
Crossref
A. I. Kochetkov & O. D. Ostroumova. (2019) Optimization of Pharmacotherapy with Direct Oral Anticoagulants: the Need to Choose the Right Dosage Regimen. Rational Pharmacotherapy in Cardiology 15:4, pages 593-603.
Crossref
Crossref
J.L. Llisterri Caro, S. Cinza-Sanjurjo, J. Polo Garcia & M.A. Prieto Díaz. (2019) Utilización de los anticoagulantes orales de acción directa en Atención Primaria de España. Posicionamiento de SEMERGEN ante la situación actual. Medicina de Familia. SEMERGEN 45:6, pages 413-429.
Crossref
Crossref
Hiroshi Inoue, Michiaki Umeyama, Takako Yamada, Hiroyuki Hashimoto, Akira Komoto & Masahiro Yasaka. (2019)
Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the
STANDARD
study
. Journal of Arrhythmia 35:3, pages 506-514.
Crossref
Crossref
Moutaz El Kadri, Nooshin Bazargani, Mohamed Farghaly, Rauf Mohamed, Nancy Awad, Ashok Natarajan, Prathamesh Pathak, Ahmed Ghorab, Nader El Kakoun, Mirko Savone, Sid Ahmed Kherraf, Jack Mardekian & Manuela Di Fusco. (2019) Profiling Clinical Characteristics and Treatment Patterns Among Non-Valvular Atrial Fibrillation Patients: A Real-World Analysis in Dubai, United Arab Emirates. Open Medicine Journal 6:1, pages 33-41.
Crossref
Crossref
Zhe Sun, Yuqi Liu, Ye Zhang, Xinhong Guo & Yong Xu. (2019) Differences in safety and efficacy of oral anticoagulants in patients with non‐valvular atrial fibrillation: A Bayesian analysis. International Journal of Clinical Practice 73:4, pages e13308.
Crossref
Crossref
Carlos Escobar, Julio Martí-Almor, Alejandro Pérez Cabeza & M. José Martínez-Zapata. (2019) Anticoagulantes orales directos frente a antagonistas de la vitamina K en pacientes con fibrilación auricular de la práctica clínica: revisión sistemática y metanálisis. Revista Española de Cardiología 72:4, pages 305-316.
Crossref
Crossref
Carlos Escobar, Julio Martí-Almor, Alejandro Pérez Cabeza & M. José Martínez-Zapata. (2019) Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis. Revista Española de Cardiología (English Edition) 72:4, pages 305-316.
Crossref
Crossref
Paolo Verdecchia, Antonio D’Onofrio, Vincenzo Russo, Francesco Fedele, Francesco Adamo, Giulia Benedetti, Fabio Ferrante, Corrado Lodigiani, Francesco Paciullo, Adolfo Aita, Claudia Bartolini, Maria Gabriella Molini, Andrea Di Lenarda, Carmine Mazzone, Lorenza Scotti, Elena Paola Lanati & Arianna Iorio. (2019) Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study. Journal of Cardiovascular Medicine 20:2, pages 66-73.
Crossref
Crossref
Gregory Y. H. Lip. (2019) The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. International Journal of Clinical Practice 73:2, pages e13285.
Crossref
Crossref
Hyung Ki JeongKi Hong LeeHyung Wook ParkNam Sik YoonMin Chul KimNuri LeeJi Sung KimYoungkeun AhnMyung Ho JeongJong Chun ParkJeong Gwan Cho. (2019) Real World Comparison of Rivaroxaban and Warfarin in Korean Patients with Atrial Fibrillation: Propensity Matching Cohort Analysis. Chonnam Medical Journal 55:1, pages 54.
Crossref
Crossref
Lisa Riesinger & Reza Wakili. (2019) Novel Oral Anticoagulants – Do Real-world Data Support our Expectations?. European Journal of Arrhythmia & Electrophysiology 5:1, pages 48.
Crossref
Crossref
Craig I. Coleman, Reinhold Kreutz, Nitesh Sood, Thomas J. Bunz, Anna-Katharina Meinecke, Daniel Eriksson & William L. Baker. (2019) Rivaroxaban’s Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis. Clinical and Applied Thrombosis/Hemostasis 25, pages 107602961986853.
Crossref
Crossref
Gregory Y.H. LipAllison KeshishianXiaoyan LiMelissa HamiltonCristina MasseriaKiran GuptaXuemei LuoJack MardekianKeith FriendAnagha NadkarniXianying PanOnur BaserSteven Deitelzweig. (2018) Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke 49:12, pages 2933-2944.
Crossref
Crossref
Jean Dallongeville, Frédéric Sacher, Stéphane Bouée, Corinne Emery, Isabelle Bureau, Julie Gourmelen & Laurent Fauchier. (2018) Xafran, a drug utilization study of rivaroxaban in stroke prevention in atrial fibrillation in France using a claim database. Therapies 73:6, pages 449-460.
Crossref
Crossref
Amgad Mentias, Ghanshyam Shantha, Pulkit Chaudhury & Mary S. Vaughan Sarrazin. (2018) Assessment of Outcomes of Treatment With Oral Anticoagulants in Patients With Atrial Fibrillation and Multiple Chronic Conditions. JAMA Network Open 1:5, pages e182870.
Crossref
Crossref
Paulus Kirchhof, Ghazi Radaideh, Young-Hoon Kim, Fernando Lanas, Sylvia Haas, Pierre Amarenco, Alexander G.G. Turpie, Miriam Bach, Marc Lambelet, Susanne Hess & A. John Camm. (2018) Global Prospective Safety Analysis of Rivaroxaban. Journal of the American College of Cardiology 72:2, pages 141-153.
Crossref
Crossref
Natalia Cullell, Caty Carrera, Elena Muiño, Nuria Torres, Jerzy Krupinski & Israel Fernandez-Cadenas. (2018) Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants. Oncotarget 9:49, pages 29238-29258.
Crossref
Crossref
A John Camm & Keith A A Fox. (2018) Strengths and weaknesses of ‘real-world’ studies involving non-vitamin K antagonist oral anticoagulants. Open Heart 5:1, pages e000788.
Crossref
Crossref
Craig I. Coleman, W. Frank Peacock & Matthias Antz. (2018) Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German Practice. Heart, Lung and Circulation 27:3, pages 390-393.
Crossref
Crossref
Marco ProiettiImma RomanazziGiulio Francesco RomitiAlessio FarcomeniGregory Y.H. Lip. (2018) Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation. Stroke 49:1, pages 98-106.
Crossref
Crossref
Craig I. Coleman, Tatsiana Vaitsiakhovich, Elaine Nguyen, Erin R. Weeda, Nitesh A. Sood, Thomas J. Bunz, Bernhard Schaefer, Anna‐Katharina Meinecke & Daniel Eriksson. (2018) Agreement between coding schemas used to identify bleeding‐related hospitalizations in claims analyses of nonvalvular atrial fibrillation patients. Clinical Cardiology 41:1, pages 119-125.
Crossref
Crossref
Nina Haagenrud Schultz, Hoa Thi Tuyet Tran, Stine Bjørnsen, Carola Elisabeth Henriksson, Per Morten Sandset & Pål Andre Holme. (2017) The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor. Thrombosis Journal 15:1.
Crossref
Crossref
Liping Zhang, Gary Peters, Lloyd Haskell, Purve Patel, Partha Nandy & Kenneth Todd Moore. (2017) A Cross‐Study Analysis Evaluating the Effects of Food on the Pharmacokinetics of Rivaroxaban in Clinical Studies. The Journal of Clinical Pharmacology 57:12, pages 1607-1615.
Crossref
Crossref
Ying Bai, Xu-Bo Shi, Chang-Sheng Ma & Gregory Y.H. Lip. (2017) Meta-Analysis of Effectiveness and Safety of Oral Anticoagulants in Atrial Fibrillation With Focus on Apixaban. The American Journal of Cardiology 120:9, pages 1689-1695.
Crossref
Crossref
. (2017) INSIDE INDUSTRY. Asia-Pacific Biotech News 21:10, pages 38-51.
Crossref
Crossref
Laura Ueberham, Nikolaos Dagres, Tatjana S. Potpara, Andreas Bollmann & Gerhard Hindricks. (2017) Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation. Advances in Therapy 34:10, pages 2274-2294.
Crossref
Crossref
George NtaiosVasileios PapavasileiouKonstantinos MakaritsisKonstantinos VemmosPatrik MichelGregory Y.H. Lip. (2017) Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation. Stroke 48:9, pages 2494-2503.
Crossref
Crossref
Craig I. ColemanW. Frank PeacockThomas J. BunzMark J. Alberts. (2017) Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Stroke 48:8, pages 2142-2149.
Crossref
Crossref
. (2017) The year in cardiology 2016: arrhythmias and cardiac implantable electronic devices. Cardiologia Croatica 12:5-6, pages 240-253.
Crossref
Crossref
Tomoyuki Kawada. (2017) Letter re: Early start of DOAC after ischemic stroke: Risk of intracranial hemorrhage and recurrent events. Neurology 88:21, pages 2068-2068.
Crossref
Crossref
Tomoyuki Kawada. (2017) Vitamin K and direct oral anticoagulants in patients with major bleeding: Risk assessment. International Journal of Cardiology 235, pages 199.
Crossref
Crossref
Ying BaiHai DengAlena ShantsilaGregory Y.H. Lip. (2017) Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation. Stroke 48:4, pages 970-976.
Crossref
Crossref
Craig Ian Coleman & Matthias Antz. (2017) Real-world evidence with apixaban for stroke prevention in patients with nonvalvular atrial fibrillation in Germany: a retrospective study (REASSESS). Internal and Emergency Medicine 12:3, pages 419-422.
Crossref
Crossref
Tomoyuki Kawada. (2017) Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin. European Journal of Internal Medicine 38, pages e20.
Crossref
Crossref
Tomoyuki Kawada. (2017) Risk assessment of cerebral microbleeds and white matter hyperintensities in patients with non-valvular atrial fibrillation. Journal of the Neurological Sciences 373, pages 249.
Crossref
Crossref
Riccardo Cappato, Gerhard Hindricks & Jan Steffel. (2017) The Year in Cardiology 2016: arrhythmias and cardiac implantable electronic devices. European Heart Journal, pages ehw629.
Crossref
Crossref
Boyoung Joung. (2017) Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients. Korean Circulation Journal 47:6, pages 833.
Crossref
Crossref
Farhan Shahid, Eduard Shantsila & Gregory Y.H. Lip. (2016) What do the guidelines suggest for non-vitamin K antagonist oral anticoagulant use for stroke prevention in atrial fibrillation?. European Heart Journal Supplements 18:suppl I, pages I18-I24.
Crossref
Crossref
Farhan Shahid, Eduard Shantsila & Gregory Y. H. Lip. (2016) Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention. F1000Research 5, pages 2887.
Crossref
Crossref